NeoGenomics, Inc. (NEO) Director Sells $208,000.00 in Stock

NeoGenomics, Inc. (NASDAQ:NEO) Director Lynn A. Tetrault sold 13,000 shares of NeoGenomics stock in a transaction on Monday, November 19th. The stock was sold at an average price of $16.00, for a total value of $208,000.00. Following the transaction, the director now owns 40,234 shares in the company, valued at approximately $643,744. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of NEO opened at $15.99 on Friday. The stock has a market capitalization of $1.46 billion, a P/E ratio of 266.50 and a beta of -0.01. NeoGenomics, Inc. has a 12-month low of $7.08 and a 12-month high of $19.04. The company has a debt-to-equity ratio of 0.32, a quick ratio of 3.98 and a current ratio of 4.13.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, October 30th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. The firm had revenue of $69.10 million for the quarter, compared to analyst estimates of $66.13 million. NeoGenomics had a net margin of 1.70% and a return on equity of 2.63%. NeoGenomics’s revenue was up 16.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.01 EPS. Analysts expect that NeoGenomics, Inc. will post 0.11 earnings per share for the current year.

Several research firms have recently commented on NEO. BidaskClub lowered NeoGenomics from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 17th. Scotiabank reiterated an “average” rating and set a $24.00 price target on shares of NeoGenomics in a report on Friday, November 16th. Zacks Investment Research upgraded NeoGenomics from a “hold” rating to a “strong-buy” rating and set a $21.00 price target on the stock in a report on Saturday, November 3rd. Benchmark set a $22.00 price target on NeoGenomics and gave the stock a “buy” rating in a report on Thursday, November 1st. Finally, Raymond James lifted their price target on NeoGenomics from $16.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, October 31st. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $20.08.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. First Light Asset Management LLC raised its holdings in NeoGenomics by 8.4% in the 2nd quarter. First Light Asset Management LLC now owns 5,162,063 shares of the medical research company’s stock valued at $67,675,000 after buying an additional 401,731 shares during the period. BlackRock Inc. raised its holdings in NeoGenomics by 22.4% in the 3rd quarter. BlackRock Inc. now owns 5,079,026 shares of the medical research company’s stock valued at $77,960,000 after buying an additional 929,697 shares during the period. Vanguard Group Inc. raised its holdings in NeoGenomics by 24.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,839,641 shares of the medical research company’s stock valued at $58,939,000 after buying an additional 743,245 shares during the period. Artisan Partners Limited Partnership raised its holdings in NeoGenomics by 0.7% in the 2nd quarter. Artisan Partners Limited Partnership now owns 2,175,072 shares of the medical research company’s stock valued at $28,515,000 after buying an additional 14,583 shares during the period. Finally, Eagle Asset Management Inc. purchased a new stake in NeoGenomics in the 3rd quarter valued at about $33,116,000. Hedge funds and other institutional investors own 80.28% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by WKRB News and is the property of of WKRB News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.wkrb13.com/2018/11/24/neogenomics-inc-neo-director-sells-208000-00-in-stock.html.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Read More: What is Compound Interest?

Insider Buying and Selling by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply